GeneDx Holdings Corp. (WGSWW)
| Market Cap | 2.01B -26.5% |
| Revenue (ttm) | 427.54M +40.0% |
| Net Income | -21.02M |
| EPS | -0.73 |
| Shares Out | 29.29M |
| PE Ratio | n/a |
| Forward PE | 70.82 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,534 |
| Open | 0.0058 |
| Previous Close | 0.0062 |
| Day's Range | 0.0058 - 0.0062 |
| 52-Week Range | 0.0041 - 0.1900 |
| Beta | 2.19 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 4, 2026 |
About WGSWW
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
News
GeneDx to Report First Quarter 2026 Financial Results on Monday, May 4, 2026
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced it will release financial results for the first quarter of 2026 after the market closes on Monday, May 4, 2026.
Cathie Wood Just Bought This Small Cap Stock Seven Days Straight: Should Investors Take Note?
Cathie Wood‘s Ark Invest makes trades across its ETFs every trading day. Those trades are sometimes closely monitored by investors when they involve new stock picks or large trades.
Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing
GAITHERSBURG, Md.--(BUSINESS WIRE)--Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing.
GeneDx Holdings Transcript: Barclays 28th Annual Global Healthcare Conference
Significant expansion efforts are underway to move advanced genetic testing from niche expert use to broader pediatric, NICU, and prenatal markets, supported by dedicated sales teams and new customer ...
GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C
GAITHERSBURG, Md.--(BUSINESS WIRE)--Announcing GeneDx's new genetic testing program with Zevra Therapeutics to support patients with suspected Niemann–Pick disease type C (NPC).
GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic Leadership
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced scientific contributions to be pr...
HALPER SADEH LLC ENCOURAGES GENEDX HOLDINGS CORP. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is invest...
GeneDx to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) announced that company management will participate in the upcoming TD Cowen and Barclays healthcare investor conferences.
These Analysts Slash Their Forecasts On GeneDx After Q4 Results
GeneDx Holdings Corp (NASDAQ: WGS) reported better-than-expected fourth-quarter financial results on Monday.
GeneDx Holdings Earnings Call Transcript: Q4 2025
Q4 2025 saw 27% revenue growth and 71% gross margin, driven by exome/genome testing and market expansion. 2026 guidance projects $540M–$555M revenue and 33%–35% volume growth, with major investments i...
INSERTING and REPLACING GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2025.
GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2025.
TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List of the World's Most Influential Leaders in Health
GAITHERSBURG, Md.--(BUSINESS WIRE)--TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List.
GeneDx to Report Fourth Quarter 2025 Financial Results on Monday, February 23, 2026
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) announced it will release financial results for the fourth quarter of 2025 before the market opens on Monday, February 23, 2026.
Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties...
GeneDx Holdings Transcript: 44th Annual J.P. Morgan Healthcare Conference
Achieved strong growth in 2025 with $427M revenue and 70%+ margins, expanding into new markets and leveraging the industry-leading Infinity database. Early diagnosis and precision medicine remain cent...
Why is GeneDx stock crashing on Monday?
GeneDx stock (NASDAQ: WGS) plunged 14% on Monday after the genomics testing company released preliminary full-year 2025 results that met expectations. But the company unveiled 2026 guidance that inves...
GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx reported high growth and profitability in preliminary results for the fourth quarter and full year of 2025 and issued 2026 guidance.
GeneDx and Komodo Health Partner to Build the World's Most Complete Longitudinal Rare Disease Dataset
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Komodo Health Partner to Build the World's Most Complete Longitudinal Rare Disease Dataset.
GeneDx Announces GenomeDx Prenatal™, Expanding Industry-Leading Genomic Diagnosis Into Prenatal Care
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announced GenomeDx Prenatal™, a whole genome sequencing test that delivers fast, comprehensive insights when fetal anomalies are identified.
GeneDx Appoints Dr. Linda Genen as Chief Medical Officer to Accelerate the Future of Genomic-First Care
GAITHERSBURG, Md.--(BUSINESS WIRE)--Dr. Linda Genen named CMO to further strengthen GeneDx's commitment to delivering earlier answers and better outcomes through genomic insights.
GeneDx Leads Rare Disease Genomics with Unmatched Research and Clinical Impact in 2025
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announced a record-setting year for its research programs, reinforcing its position as the global leader in rare disease genomics.
GeneDx to Present at the J.P. Morgan 2026 Healthcare Conference
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announced that company management will participate in the 44th Annual J.P. Morgan Healthcare Conference from January 12-15 in San Francisco.
JAMA (Journal of the American Medical Association) Recognizes GUARDIAN Newborn Genomic Screening Study Among Its Research of the Year
GAITHERSBURG, Md.--(BUSINESS WIRE)--The GUARDIAN study has been recognized as one of the most impactful scientific contributions published across all JAMA journals this year.
Eight stock picks to play one of the healthiest corners of the market
The healthcare sector of the U.S. stock market as a whole is cheaply priced, which can make it attractive to investors concerned that the S&P 500 has gotten too expensive several years into a bull mar...